Insulin aspart (Fiasp) for treating diabetes mellitus

Endocrine and metabolic

2 January 2024

Published on 02 Jan 2024
Last Updated on 02 Jan 2024

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended insulin aspart (Fiasp) for inclusion on the MOH List of Subsidised Drugs for treating diabetes mellitus due to limited clinical need and unfavourable cost effectiveness compared with alternative treatments.

Insulin aspart (Fiasp) for treating diabetes mellitus (Published 2 Jan 2024) [PDF, 88 KB]